StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)

StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report sent to investors on Monday morning. The firm issued a sell rating on the stock.

Bio-Path Stock Up 20.0 %

Shares of NASDAQ BPTH opened at $0.18 on Monday. The stock has a fifty day moving average price of $0.16 and a 200 day moving average price of $0.60. Bio-Path has a 1-year low of $0.12 and a 1-year high of $4.55.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.